Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kuypers, D. R. J.
Right arrow Articles by Vanrenterghem, Y. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuypers, D. R. J.
Right arrow Articles by Vanrenterghem, Y. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 2051-2054
© 2002 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Tailoring immunosuppressive therapy

Dirk R. J. Kuypers and Y. C. Vanrenterghem

Department of Nephrology and Renal Transplantation, University of Leuven, Belgium

Keywords: calcineurin inhibitors; corticosteroids; low-toxicity immunosuppressive therapy; mTOR inhibitors; tailoring

The first 150 words of the full text of this article appear below.

Introduction

In the last decade, a paradigm shift has occurred in the field of renal transplantation. The use of new and powerful immunosuppressive drugs has led to excellent short-term patient and graft survival and very low acute rejection (AR) rates. Two burning questions have become paramount. The first is how can we improve long-term patient and graft survival despite the fact that more elderly patients are transplanted and that the growing demand for donor organs is more often counterbalanced by the use of marginal donors? The second question is how should we tailor the optimal immunosuppressive therapy to the individual patient profile? It is clear, for example, that a patient suffering from osteoporosis and diabetes mellitus will not benefit from the same immunosuppressive drug protocol as a patient who has severe arterial hypertension and hyperlipidaemia (Table 1Go). The older principle of ‘one fits all’ has become more and more obsolete. . . . [Full Text of this Article]

Corticosteroids

Calcineurin inhibitors

mTOR inhibitors

Drugs that enable the use of lower concomitant drug concentrations

Conclusion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. Kramer, V. Stel, C. Zoccali, J. Heaf, D. Ansell, C. Gronhagen-Riska, T. Leivestad, K. Simpson, R. Palsson, M. Postorino, et al.
An update on renal replacement therapy in Europe: ERA-EDTA Registry data from 1997 to 2006
Nephrol. Dial. Transplant., December 1, 2009; 24(12): 3557 - 3566.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
Z. Varghese, R. Fernando, J. F. Moorhead, S. H. Powis, and X. Z. Ruan
Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts
Am J Physiol Renal Physiol, July 1, 2005; 289(1): F43 - F48.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Anglicheau, M. Flamant, M. H. Schlageter, F. Martinez, B. Cassinat, P. Beaune, C. Legendre, and E. Thervet
Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2409 - 2414.
[Abstract] [Full Text] [PDF]